Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel Compared With Adapalene Topical Gel, 0.1%; Benzoyl Peroxide Topical Gel, 2.5% and Topical Gel Vehicle in Subjects With Acne Vulgaris
Brief Summary: This was a multi-center, randomized, double-blind, parallel group study with 12 weeks of treatment of acne vulgaris. Efficacy and safety evaluations were performed at Screening (safety only), Baseline and Weeks 1, 2, 4, 8 and 12. All Investigator's Global Assessment evaluators and lesion counters must be trained and approved by Galderma. The evaluator of a participant should remain the same during the study.

The primary objective was to demonstrate the superiority in efficacy and assess safety of adapalene/benzoyl peroxide topical gel (adapalene/benzoyl peroxide gel) versus adapalene topical gel, 0.1% (adapalene monad); benzoyl peroxide topical gel, 2.5% (benzoyl peroxide monad) and topical gel vehicle (gel vehicle) in the treatment of acne vulgaris for up to 12 weeks.


Options:
A: Arm Label: Adapalene/Benzoyl Peroxide Gel; Type: EXPERIMENTAL; Interventions: Drug: Adapalene/Benzoyl Peroxide | Arm Label: Adapalene Gel, 0.1%; Type: EXPERIMENTAL; Interventions: Drug: Adapalene Gel, 0.1% | Arm Label: Benzoyl Peroxide Gel 2.5%; Type: EXPERIMENTAL; Interventions: Drug: Benzoyl Peroxide Gel 2.5% | Arm Label: Gel Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Gel Vehicle | Intervention Type: DRUG; Name: Adapalene/Benzoyl Peroxide; Assigned to Arm(s): Adapalene/Benzoyl Peroxide Gel | Intervention Type: DRUG; Name: Adapalene Gel, 0.1%; Assigned to Arm(s): Adapalene Gel, 0.1% | Intervention Type: DRUG; Name: Benzoyl Peroxide Gel 2.5%; Assigned to Arm(s): Benzoyl Peroxide Gel 2.5% | Intervention Type: DRUG; Name: Gel Vehicle; Assigned to Arm(s): Gel Vehicle
B: Arm Label: Duac & taz; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene | Arm Label: Acanya & taz; Type: ACTIVE_COMPARATOR; Interventions: Drug: clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene | Intervention Type: DRUG; Name: Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene; Assigned to Arm(s): Duac & taz | Intervention Type: DRUG; Name: clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene; Assigned to Arm(s): Acanya & taz
C: Arm Label: CD0271 0.3% /CD1579 2.5% Gel; Type: EXPERIMENTAL; Interventions: Drug: CD0271 0.3% / CD1579 2.5% | Arm Label: CD0271 0.1% / CD1579 2.5%; Type: ACTIVE_COMPARATOR; Interventions: Drug: CD0271 0.1% / CD1579 2.5% | Arm Label: Topical Gel Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Topical Gel Vehicle | Intervention Type: DRUG; Name: CD0271 0.3% / CD1579 2.5%; Assigned to Arm(s): CD0271 0.3% /CD1579 2.5% Gel | Intervention Type: DRUG; Name: CD0271 0.1% / CD1579 2.5%; Assigned to Arm(s): CD0271 0.1% / CD1579 2.5% | Intervention Type: DRUG; Name: Topical Gel Vehicle; Assigned to Arm(s): Topical Gel Vehicle
D: Arm Label: Part 1: ABPO Forte Gel; Type: EXPERIMENTAL; Interventions: Drug: ABPO Forte Gel | Arm Label: Part 1: ABPO Forte Vehicle Gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle gel | Arm Label: Part 2: ABPO Forte Gel; Type: EXPERIMENTAL; Interventions: Drug: ABPO Forte Gel | Arm Label: Part 2: ABPO Forte Vehicle Gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle gel | Intervention Type: DRUG; Name: ABPO Forte Gel; Assigned to Arm(s): Part 1: ABPO Forte Gel, Part 2: ABPO Forte Gel | Intervention Type: DRUG; Name: Vehicle gel; Assigned to Arm(s): Part 1: ABPO Forte Vehicle Gel, Part 2: ABPO Forte Vehicle Gel

Answer: A